Clinical Trial Update: Testing Afatinib as a Potential Targeted Treatment in Cancers With HER2 Genetic Changes (MATCH-Subprotocol B) [Phase 2]

View source ↗

Summary

A Phase 2 MATCH subprotocol study evaluates afatinib for cancers with HER2 genetic changes; results were posted in 2022 and the trial status is active but not r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Multiple Myeloma
• Solid Tumors

Drugs mentioned

• Afatinib (afatinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2022-11-29